Yesterday, June 6, 2016, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $185.85 to $2,531,705.11.

Highlighted Stocks Traded by Insiders:

Endologix (ELGX) - FREE Research Report

Waller Gregory D, who is Director at Endologix, sold 7,800 shares at $12.86 on June 6, 2016. Following this transaction, the Director owned 27,728 shares meaning that the stake was reduced by 21.95% with the 7,800-share transaction.

The shares most recently traded at $12.90, up $0.04, or 0.31% since the insider transaction. Historical insider transactions for Endologix go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 6,500
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 6,500
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 10,780

The average volume for Endologix has been 1.1 million shares per day over the past 30 days. Endologix has a market cap of $1.0 billion and is part of the health care sector and health services industry. Shares are up 31.01% year-to-date as of the close of trading on Monday.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. Currently, there are 5 analysts who rate Endologix a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ELGX - FREE

TheStreet Quant Ratings

rates Endologix as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full

Endologix Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Seattle Genetics (SGEN) - FREE Research Report

Cline Darren S, who is EVP, Commercial at Seattle Genetics, sold 3,366 shares at $42.07 on June 6, 2016. Following this transaction, the EVP, Commercial owned 42,747 shares meaning that the stake was reduced by 7.3% with the 3,366-share transaction.

The shares most recently traded at $43.04, up $0.97, or 2.25% since the insider transaction. Historical insider transactions for Seattle Genetics go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 87,473
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 87,473
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 87,473

The average volume for Seattle Genetics has been 1.0 million shares per day over the past 30 days. Seattle Genetics has a market cap of $6.1 billion and is part of the health care sector and drugs industry. Shares are down 2.9% year-to-date as of the close of trading on Monday.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. Currently, there are 6 analysts who rate Seattle Genetics a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SGEN - FREE

TheStreet Quant Ratings

rates Seattle Genetics as a

sell

. Among the areas we feel are negative, one of the most important has been the company's poor growth in earnings per share. Get the full

Seattle Genetics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Joint (JYNT) - FREE Research Report

Orwasher David M, who is Chief Dev. & Strategy Officer at Joint, sold 4,400 shares at $3.11 on June 6, 2016. Following this transaction, the Chief Dev. & Strategy Officer owned 163,375 shares meaning that the stake was reduced by 2.62% with the 4,400-share transaction.

The shares most recently traded at $2.99, down $0.12, or 4.14% since the insider transaction. Historical insider transactions for Joint go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,400
  • 12-Week # shares bought: 36,225
  • 12-Week # shares sold: 2,400
  • 24-Week # shares bought: 36,225
  • 24-Week # shares sold: 2,400

The average volume for Joint has been 28,600 shares per day over the past 30 days. Joint has a market cap of $39.8 million and is part of the health care sector and health services industry. Shares are down 49.75% year-to-date as of the close of trading on Monday.

The Joint Corp. develops, owns, operates, franchises, supports, and manages chiropractic clinics in the United States. As of March 17, 2016, it operated and franchised approximately 330 clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona. Currently, there are 2 analysts who rate Joint a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JYNT - FREE

TheStreet Quant Ratings

rates Joint as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Joint Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.